Levofloxacin prophylaxis in patients with myeloma - Authors' reply.

Drayson, Mark T; Bowcock, Stella; Planche, Tim; Iqbal, Gulnaz; Pratt, Guy; Yong, Kwee; Dunn, Janet A

Drayson, Mark T; Bowcock, Stella; Planche, Tim; Iqbal, Gulnaz; Pratt, Guy; Yong, Kwee; Dunn, Janet A.

Afiliação

Drayson MT; School of Immunity and Infection, University of Birmingham, Birmingham B15 2TT, UK. Electronic address: M.T.Drayson@bham.ac.uk.
Bowcock S; King's College Hospital NHS Trust, London, UK.
Planche T; Department of Medical Microbiology, St George's, University of London, London, UK.
Iqbal G; Warwick Clinical Trials Unit, University of Warwick, Coventry, UK.
Pratt G; University Hospitals Birmingham NHS Trust, Birmingham, UK.
Yong K; Department of Haematology, UCL Cancer Institute, London, UK.
Dunn JA; Warwick Clinical Trials Unit, University of Warwick, Coventry, UK.

Lancet Oncol ; 21(2): e69, 2020 02.

Article em En | MEDLINE | ID: mdl-32007200

Assuntos

Levofloxacino; Mieloma Múltiplo; Antibacterianos; Antibioticoprofilaxia; Método Duplo-Cego; Humanos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Levofloxacino / Mieloma Múltiplo Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google